These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 27987632)

  • 1. The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight.
    Hatswell AJ; Porter J; Lee D; Hertel N; Latimer NR
    Value Health; 2016 Dec; 19(8):1055-1058. PubMed ID: 27987632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How much does a diabetes out-patient appointment actually cost? An argument for PLICS.
    Grant P
    J Health Organ Manag; 2015; 29(2):154-69. PubMed ID: 25800330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches.
    Clement Nee Shrive FM; Ghali WA; Donaldson C; Manns BJ
    Health Econ; 2009 Apr; 18(4):377-88. PubMed ID: 18615835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of government subsidized pharmaceutical use in patients with diabetes or cardiovascular disease in a primary care setting: evidence from a prospective randomized trial.
    Hirst NG; Whitty JA; Synnott RL; Eley DS; Scuffham PA
    J Med Econ; 2011; 14(6):698-704. PubMed ID: 21892854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost data assessment in multinational economic evaluations: some theory and review of published studies.
    Halliday RG; Darba J
    Appl Health Econ Health Policy; 2003; 2(3):149-55. PubMed ID: 14984280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials.
    Taira DA; Seto TB; Siegrist R; Cosgrove R; Berezin R; Cohen DJ
    Am Heart J; 2003 Mar; 145(3):452-8. PubMed ID: 12660668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of stroke using patient-level data: a critical review of the literature.
    Luengo-Fernandez R; Gray AM; Rothwell PM
    Stroke; 2009 Feb; 40(2):e18-23. PubMed ID: 19109540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
    Dietrich ES
    Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of transparency of cost estimates in economic evaluations of patient safety programmes.
    Fukuda H; Imanaka Y
    J Eval Clin Pract; 2009 Jun; 15(3):451-9. PubMed ID: 19366392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder.
    Zhang JJ; Nellesen D; Ludlam WH; Neary MP
    J Med Econ; 2016; 19(4):374-85. PubMed ID: 26629745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The distribution of health care costs and their statistical analysis for economic evaluation.
    Briggs A; Gray A
    J Health Serv Res Policy; 1998 Oct; 3(4):233-45. PubMed ID: 10187204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact model of a 5-grass sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis.
    Ivanova JI; Kelkar S; King S; Birnbaum HG; Hocker S; Phipps R; Lankow R
    J Med Econ; 2015; 18(11):909-18. PubMed ID: 26481690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A general framework for classifying costing methods for economic evaluation of health care.
    Špacírová Z; Epstein D; García-Mochón L; Rovira J; Olry de Labry Lima A; Espín J
    Eur J Health Econ; 2020 Jun; 21(4):529-542. PubMed ID: 31960181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. At what price significance? The effect of price estimates on statistical inference in economic evaluation.
    Rittenhouse BE; Dulisse B; Stinnett AA
    Health Econ; 1999 May; 8(3):213-9. PubMed ID: 10348416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.